S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

$16.48
+1.78 (+12.11%)
(As of 02/21/2024 ET)
Today's Range
$15.09
$16.50
50-Day Range
$14.06
$20.73
52-Week Range
$11.03
$21.22
Volume
4.09 million shs
Average Volume
920,982 shs
Market Capitalization
$2.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.91

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
14.7% Upside
$18.91 Price Target
Short Interest
Bearish
6.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of NeoGenomics in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$38,702 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.27) to ($0.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.23 out of 5 stars

Medical Sector

798th out of 932 stocks

Testing Laboratories Industry

2nd out of 2 stocks


NEO stock logo

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

NEO Stock News Headlines

NeoGenomics (NASDAQ:NEO) Given "Outperform" Rating at William Blair
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Q4 2023 Neogenomics Inc Earnings Call
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
Recap: NeoGenomics Q4 Earnings
NeoGenomics: Q4 Earnings Snapshot
NeoGenomics's Earnings Outlook
NeoGenomics Q4 2023 Earnings Preview
NeoGenomics (NEO) to Release Quarterly Earnings on Tuesday
NeoGenomics: Progress, But A New Uncertainty
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/22/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Testing laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$18.91
High Stock Price Target
$24.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+14.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-144,250,000.00
Pretax Margin
-18.67%

Debt

Sales & Book Value

Annual Sales
$591.64 million
Book Value
$7.90 per share

Miscellaneous

Free Float
125,809,000
Market Cap
$2.10 billion
Optionable
Optionable
Beta
1.12

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 61)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 58)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Vishal Sikri (Age 47)
    President of Advanced Diagnostics Division
    Comp: $1.21M
  • Mr. Warren Stone (Age 51)
    President of Clinical Division
    Comp: $722.79k
  • Ms. Cynthia J. Dieter (Age 49)
    Chief Accounting Officer
  • Mr. Greg Sparks
    Chief Technology Officer
  • Ms. Kendra Sweeney
    Vice President of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 40)
    General Counsel & Corporate Secretary
  • Mr. Hutan Hashemi J.D. (Age 45)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer














NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price target for 2024?

12 brokerages have issued twelve-month price objectives for NeoGenomics' shares. Their NEO share price targets range from $17.00 to $24.00. On average, they expect the company's stock price to reach $18.91 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2024?

NeoGenomics' stock was trading at $16.18 at the start of the year. Since then, NEO stock has increased by 1.9% and is now trading at $16.48.
View the best growth stocks for 2024 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The medical research company earned $121.30 million during the quarter, compared to the consensus estimate of $125.09 million. NeoGenomics had a negative trailing twelve-month return on equity of 4.11% and a negative net margin of 14.87%. The firm's revenue for the quarter was down 3.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.04 EPS.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.12%), Brown Advisory Inc. (7.57%), First Light Asset Management LLC (3.08%), Dimensional Fund Advisors LP (2.36%), Schroder Investment Management Group (1.95%) and Northern Trust Corp (1.25%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
This page (NASDAQ:NEO) was last updated on 2/22/2024 by MarketBeat.com Staff